Literature DB >> 2816967

Low-antigen-content diet in the treatment of patients with mixed cryoglobulinemia.

C Ferri1, M Pietrogrande, R Cecchetti, A Tavoni, A Cefalo, G Buzzetti, C Vitali, S Bombardieri.   

Abstract

PURPOSE: The effects of a low-antigen-content diet (LAC diet) versus a standard normocaloric diet on the signs and symptoms of mixed cryoglobulinemia (MC) were compared in a crossover randomized study. PATIENTS AND METHODS: The study consisted of 24 outpatients with MC, and was carried out in a 48-week period. After 18 weeks of either the LAC or the placebo diet, patients returned to a totally unrestricted diet for 12 weeks (washout period) and crossed over to the second half of the study for the other 18 weeks.
RESULTS: After three weeks of the restricted LAC diet, the cryocrit decreased from 3.5 +/- 3.4% (mean +/- SD) to 2.3 +/- 2.0% (p less than 0.01), and the circulating immune complex levels decreased from 48 +/- 30% to 39 +/- 34% (p less than 0.01). At the same time, the purpura score (p less than 0.05), glutamic pyruvic transaminase level (p less than 0.01), and gamma glutamyl transferase level (p less than 0.001) significantly improved. Splenic reticuloendothelial function, measured as the half-life of heat-damaged autologous red cells, decreased from 41 +/- 21 minutes to 21 +/- 10 minutes (p less than 0.005). In contrast, no significant parallel clinical, biochemical, and immunologic changes occurred in the same patients during the placebo (standard normocaloric) diet.
CONCLUSION: These data show that an LAC diet decreases the amount of circulating immune complexes in MC and can modify certain signs and symptoms of the disease. These effects of the LAC diet may be explained by postulating a functional restoration of the mononuclear phagocytic system.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2816967     DOI: 10.1016/s0002-9343(89)80607-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  12 in total

1.  Antibodies against hepatitis C virus in mixed cryoglobulinemia patients.

Authors:  C Ferri; F Greco; G Longombardo; P Palla; A Moretti; E Marzo; P V Fosella; G Pasero; S Bombardieri
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

Review 2.  Cryoglobulins and cryoglobulinemia. Diagnostic and therapeutic considerations.

Authors:  A Della Rossa; G Trevisani; S Bombardieri
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 3.  Cryoglobulins.

Authors:  C Ferri; A L Zignego; S A Pileri
Journal:  J Clin Pathol       Date:  2002-01       Impact factor: 3.411

4.  Interferon alfa-2b in mixed cryoglobulinaemia: a controlled crossover trial.

Authors:  C Ferri; E Marzo; G Longombardo; L La Civita; F Lombardini; D Giuggioli; R Vanacore; A M Liberati; A Mazzoni; F Greco
Journal:  Gut       Date:  1993       Impact factor: 23.059

5.  Effect of alpha-interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients.

Authors:  C Ferri; A L Zignego; G Longombardo; M Monti; L La Civita; F Lombardini; F Greco; A Mazzoni; G Pasero; P Gentilini
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

Review 6.  Diversity and origin of rheumatologic autoantibodies.

Authors:  M J Fritzler; M Salazar
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

7.  Primary Cutaneous Small Vessel Vasculitis.

Authors:  James P. Russell; Roger H. Weenig
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-04

Review 8.  Current treatment of hepatitis C-associated rheumatic diseases.

Authors:  Clodoveo Ferri; Marco Sebastiani; Alessandro Antonelli; Michele Colaci; A Manfredi; Dilia Giuggioli
Journal:  Arthritis Res Ther       Date:  2012-06-25       Impact factor: 5.156

9.  Hepatitis C virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of hepatitis C virus infection.

Authors:  Mahmoud Aboelneen Khattab; Mohammed Eslam; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2010-12-01       Impact factor: 0.660

Review 10.  Symptomatic cryoglobulinemia.

Authors:  A Dispenzieri
Journal:  Curr Treat Options Oncol       Date:  2000-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.